EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Risk‐Stratified Phase II Clinical Trial for Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in Pediatric, Adolescent, and Young Adult Patients in Japan

Kenichi Sakamoto, Ryu Yanagisawa iD, Rintaro Ono iD, Takehiko Doi, Tatsuya Negishi, Akiko Kada, Akiko M Saito, Hirokazu Kanegane iD, Akira Morimoto iD, Yoko Shioda, Yozo Nakazawa iD

Pediatric Blood & Cancer · 2026

DOI: 10.1002/pbc.32166 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Kenichi Sakamoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic, Epstein-Barr Virus Infections, Herpesvirus 4, Human, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, Japan Leukemia Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis (EBV‐HLH) is highly prevalent in Asia. This study evaluated the safety and efficacy of a risk‐stratified treatment guided by dexamethasone (DEX) response and plasma EBV‐DNA levels. Our goal was to optimize etoposide dosing and establish a safer EBV‐HLH treatment.

Methods

We conducted a single‐arm, multicenter, risk‐stratified Phase II clinical trial, EBV‐HLH15, for EBV‐HLH. Patients were classified into three groups based on age, DEX response, and plasma EBV‐DNA load. In the low‐risk (LR) group, etoposide was eliminated from the treatment regimen. In the intermediate‐risk and high‐risk group (IR/HR group), etoposide dosing was reduced by up to 60% compared with the HLH‐2004 study to attenuate treatment intensity, whereas rituximab was added in the HR group to maintain it.

Results

Of 56 patients suspected of EBV‐HLH enrolled, 26 (14 in LR, eight in IR, and four in HR group) were eligible for EBV‐HLH15. The median age was 3.5 years (range: 1.0–8.0). The 1‐year overall survival of the LR and IR/HR groups was 100% and 81.5% (95% confidence interval [CI] = 43.5–95.1), respectively. The event‐free survival of the LR and IR/HR groups was 78.6% (95% CI = 47.2–92.5) and 58.3% (95% CI = 27.0–80.1), respectively. Most events (9/10, mainly deterioration or recurrence of HLH) occurred within 3 weeks of treatment initiation. No patients received rituximab as scheduled in Weeks 5 and 6.

Conclusion

Risk‐stratified treatment for EBV‐HLH guided by DEX response and plasma EBV‐DNA levels after 2 weeks of treatment was safe and effective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphohistiocytosis, HemophagocyticEpstein-Barr Virus InfectionsHerpesvirus 4, HumanAntineoplastic Combined Chemotherapy ProtocolsHumansAdolescentChildMaleFemaleChild, PreschoolYoung AdultEtoposideDexamethasoneJapanInfantAdultPrognosisRituximabFollow-Up StudiesSurvival RateDNA, Viral

Stichwörter der Autor:innen

EB virus‐associated hemophagocytic lymphohistiocytosisadolescent and young adultepstein–Barr virushemophagocytic lymphohistiocytosispediatric

Substanzen

EtoposideDexamethasoneRituximabDNA, Viral

Autor:innen und Institutionen

  • Department of Pediatrics, Shinshu University School of Medicine, Matsumoto, Japan.
  • HLH/LCH Committee, Japan Children's Cancer Group.
  • Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan.
  • Division of Patient Safety, Hiroshima University Hospital, Hiroshima, Japan.
  • Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan.
  • Clinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.

ORCID-Profile: Ryu Yanagisawa, Rintaro Ono, Hirokazu Kanegane, Akira Morimoto, Yozo Nakazawa

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Leukemia Research Fund

Zitieren

APA

Sakamoto, K., Yanagisawa, R., Ono, R., Doi, T., Negishi, T., Kada, A., Saito, A. M., Kanegane, H., Morimoto, A., Shioda, Y., & Nakazawa, Y. (2026). Risk‐Stratified Phase II Clinical Trial for Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in Pediatric, Adolescent, and Young Adult Patients in Japan. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32166

Vancouver

Sakamoto K, Yanagisawa R, Ono R, Doi T, Negishi T, Kada A, et al. Risk‐Stratified Phase II Clinical Trial for Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in Pediatric, Adolescent, and Young Adult Patients in Japan. Pediatric Blood & Cancer. 2026. doi:10.1002/pbc.32166

BibTeX
@article{Sakamoto2026,
  author = {Sakamoto, Kenichi and Yanagisawa, Ryu and Ono, Rintaro and Doi, Takehiko and Negishi, Tatsuya and Kada, Akiko and Saito, Akiko M and Kanegane, Hirokazu and Morimoto, Akira and Shioda, Yoko and Nakazawa, Yozo},
  title = {Risk‐Stratified Phase II Clinical Trial for Epstein–Barr Virus‐Associated Hemophagocytic Lymphohistiocytosis in Pediatric, Adolescent, and Young Adult Patients in Japan},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/pbc.32166}
}
Kostenlos starten →